伏立康唑的安全性与剂量个体化 - Suppr

Suppr

超能文献

Safety of voriconazole and dose individualization.

作者信息

Lutsar Irja, Hodges Mike R, Tomaszewski Konrad, Troke Peter F, Wood Nolan D

出版信息

Clin Infect Dis. 2003 Apr 15;36(8):1087-8. doi: 10.1086/374248.

DOI:10.1086/374248

PMID:12684928

Abstract

摘要

相似文献

Safety of voriconazole and dose individualization.

Clin Infect Dis. 2003 Apr 15;36(8):1087-8. doi: 10.1086/374248.

The safety of voriconazole.

Clin Infect Dis. 2002 Nov 15;35(10):1273-5. doi: 10.1086/343746.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Antimicrob Agents Chemother. 2004 Jun;48(6):2166-72. doi: 10.1128/AAC.48.6.2166-2172.2004.

How many steps along the path is too far?

Clin Infect Dis. 2010 Jan 1;50(1):37-9. doi: 10.1086/648680.

Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.

Pediatr Infect Dis J. 2010 May;29(5):480-1. doi: 10.1097/INF.0b013e3181d60a82.

Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.

J Antimicrob Chemother. 2012 Mar;67(3):700-6. doi: 10.1093/jac/dkr517. Epub 2011 Dec 21.

Dosing voriconazole in an obese patient.

Clin Infect Dis. 2011 Oct;53(7):745. doi: 10.1093/cid/cir511. Epub 2011 Aug 16.

Voriconazole-associated severe hyponatremia.

Med Mycol. 2012 Jan;50(1):103-5. doi: 10.3109/13693786.2011.587210. Epub 2011 Jun 15.

Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.

Ann Pharmacother. 2008 Dec;42(12):1859-64. doi: 10.1345/aph.1L243. Epub 2008 Nov 18.

Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.

J Antimicrob Chemother. 2012 Nov;67(11):2717-24. doi: 10.1093/jac/dks258. Epub 2012 Jul 13.

引用本文的文献

Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold - A Retrospective Cohort Study.

Infect Drug Resist. 2022 Dec 16;15:7475-7484. doi: 10.2147/IDR.S391022. eCollection 2022.

Voriconazole-Induced Cholestatic Hepatotoxicity in an Immune Competent Patient.

Cureus. 2022 Jan 17;14(1):e21346. doi: 10.7759/cureus.21346. eCollection 2022 Jan.

Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the Treatment of Emerging Candida auris Using an Immunocompromised Murine Model of Disseminated Candidiasis.

Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0054921. doi: 10.1128/AAC.00549-21.

Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.

Antibiotics (Basel). 2020 Dec 8;9(12):877. doi: 10.3390/antibiotics9120877.

Voriconazole-Induced Hepatotoxicity Presenting With Severe Hepatic Encephalopathy After Liver Transplantation.

ACG Case Rep J. 2019 Feb 25;6(3):1-4. doi: 10.14309/crj.0000000000000010. eCollection 2019 Mar.

Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents.

Drugs. 2019 Jun;79(8):833-853. doi: 10.1007/s40265-019-01127-8.

Significance of monitoring plasma concentration of voriconazole in a patient with liver failure: A case report.

Medicine (Baltimore). 2017 Oct;96(42):e8039. doi: 10.1097/MD.0000000000008039.

Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.

Pediatr Infect Dis J. 2017 Jan;36(1):e1-e13. doi: 10.1097/INF.0000000000001339.

Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Curr Fungal Infect Rep. 2015 Jun;9(2):74-87. doi: 10.1007/s12281-015-0219-0. Epub 2015 Apr 16.

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

J Antimicrob Chemother. 2014 May;69(5):1162-76. doi: 10.1093/jac/dkt508. Epub 2013 Dec 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验